Belimumab efficacy in mucocutaneous lupus erythematosus: a large post-hoc analysis from five phase III clinical trials.

Objective: To determine the efficacy of belimumab on mucocutaneous manifestations of systemic lupus erythematosus (SLE) in a large integrative analysis.

Methods: Using data from five phase III clinical trials (BLISS-52; BLISS-76; BLISS-NEA; EMBRACE; BLISS-SC; N = 3086), we investigated the effect of belimumab vs placebo on top of standard therapy on inducing improvement in mucocutaneous British Isles Lupus Assessment Group (mcBILAG) and mucocutaneous SLE Disease Activity Index 2000 (mcSLEDAI-2K), and on preventing mcBILAG flares. We employed logistic and Cox regression analysis, adjusting for trial variance.

Transcriptome analysis to decipher the molecular underpinnings of response to treatment in systemic lupus erythematosus.

Objective: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterised by variable treatment responses. We investigated the transcriptional landscape associated with treatment response and resistance in SLE.

Methods: Blood was collected from 92 active patients with SLE at baseline and after 6 months (n=32 paired samples) of treatment with cyclophosphamide (n=40), rituximab (n=20), belimumab (n=23), mycophenolate mofetil (n=8) or azathioprine (n=1) and was subjected to RNA sequencing.

Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting.

Objective: Studies supporting therapeutic drug monitoring to biopharmaceuticals in systemic lupus erythematosus (SLE) are scarce. We aimed to assess anti-drug antibody (ADA) occurrence in belimumab-treated SLE patients and associations between belimumab concentrations and clinical response, serological outcomes, and adverse events.

Methods: We included 100 patients treated with intravenous belimumab.

Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways.

Objectives: Belimumab is a putative disease-modifying agent in systemic lupus erythematosus (SLE), yet the molecular underpinnings of its effects and the ability to predict early clinical response remain unexplored. To address these, we undertook a longitudinal, in-depth blood transcriptome study.

Methods: RNA-sequencing was performed in the blood of active SLE patients at baseline and following 6 months of belimumab treatment (n=45 paired samples).

Penetrating Femoral Trauma: A Report on Its Management and Outcome.

Penetrating trauma of the femur poses significant life-threatening risks due to potential complications, particularly involving the femoral structures such as the femoral artery, femoral vein, and femoral nerve. These injuries can lead to severe outcomes, especially when accompanied by soft tissue damage. Effective management requires a thorough understanding of the injury's nature, including the extent of soft tissue involvement and associated complications.